Continuous 5-fluorouracil infusion and alpha interferon in advanced cancers: a report of initial treatment results. Am J Med Sci 1991 Apr;301(4):246-9
Date
04/01/1991Pubmed ID
2012109DOI
10.1097/00000441-199104000-00003Scopus ID
2-s2.0-0025753543 (requires institutional sign-in at Scopus site) 6 CitationsAbstract
Twenty-four patients with advanced metastatic cancer were treated with continuous intravenous 5-fluorouracil infusion 200-300 mg/m2/day and alpha interferon 3 million units subcutaneously 3 times per week. The average duration of treatment was 87 days (range 22-204 days). 5-fluorouracil could be infused 66% of the planned time on treatment, and patients received an average of 60% of the planned interferon injections. Objective tumor responses were seen in 6 of 17 previously untreated patients (35%). Twenty-two of the 24 patients (92%) experienced toxicity (greater than or equal to ECOG grade II) that required treatment interruption and subsequent dose reduction predominantly for the following reasons: mucositis (67%), hand-foot syndrome (21%), and leukopenia (25%). The incidence of treatment limiting toxicity is higher than previously observed with 5-fluorouracil infusion alone. This suggests true augmentation of 5-fluorouracil effect by interferon. 5-Fluorouracil infusion and alpha interferon is a potentially useful combination that needs further evaluation in future phase II and phase III trials.
Author List
Hansen RM, Ritch PS, Libnoch JA, Anderson TMESH terms used to index this publication - Major topics in bold
AdultAged
Antineoplastic Combined Chemotherapy Protocols
Drug Evaluation
Female
Fluorouracil
Humans
Interferon Type I
Male
Middle Aged
Neoplasms
